Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 10/20 | 0.78 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.78 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | IL1B | P01584 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16209843 | 0.88 | DDB1 (1.00) | DDB1CRBNGAAALOX15IKZF3 | |
| SCHEMBL29922428 | 0.88 | DDB1 (1.00) | DDB1CRBNGAAALOX15IKZF3 | |
| SCHEMBL19953931 | 0.88 | DDB1 (1.00) | DDB1CRBNGAAALOX15IKZF3 | |
| SCHEMBL20437026 | 0.83 | DDB1 (0.78) | DDB1CRBNGAAALOX15IKZF3 | |
| SCHEMBL18900455 | 0.82 | CRBN (0.80) | DDB1CRBNGAAALOX15IKZF3 | |
| SCHEMBL18900402 | 0.81 | DDB1 (0.60) | DDB1CRBNGAAALOX15IKZF3 | |
| SCHEMBL10214943 | 0.79 | DDB1 (0.60) | DDB1CRBNGAAALOX15IKZF3 | |
| SCHEMBL30241720 | 0.79 | DDB1 (0.83) | DDB1CRBNGAAALOX15IKZF3 | |
| SCHEMBL17884399 | 0.79 | DDB1 (0.79) | DDB1CRBNGAAALOX15IKZF3 | |
| SCHEMBL16116630 | 0.79 | DDB1 (0.74) | DDB1CRBNGAAALOX15IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | ITK, IKZF2, PBK | DDB1 2437/4885CRBN 360/4885GAA 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.